Demirci Nebi S, Dogan Mutlu, Erdem Gokmen U, Kacar Sabite, Turhan Turan, Kilickap Saadettin, Cigirgan Lutfi C, Kayacetin Ertugrul, Bozkaya Yakup, Zengin Nurullah
Department of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey.
Department of Gastroenterology, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey.
Saudi J Gastroenterol. 2017 May-Jun;23(3):183-189. doi: 10.4103/sjg.SJG_483_16.
BACKGROUND/AIMS: To evaluate the prognostic significance of plasma caveolin (CAV)-1 and its association with survival and treatment response rates in metastatic pancreatic cancer (MPC).
Plasma samples were prospectively collected from 41 patients with newly diagnosed MPC. Moreover, plasma samples were collected from 48 patients with chronic pancreatitis and 41 healthy individuals (control groups) for assessing Cav-1 levels. Plasma Cav-1 levels were evaluated at baseline and after three cycles of chemotherapy in the patients with MPC.
The median Cav-1 level was 13.8 ng/mL for the patients with MPC and 12.2 ng/mL for healthy individuals (P = 0.009). The Cav-1 cut-off level was calculated as 11.6 ng/mL by using the receiver operating characteristic curve. The median overall survival and progression-free survival rates were 5 and 2.4 months, respectively, for participants with a high basal plasma Cav-1 level; the corresponding values were 10.5 and 9.4 months for participants with a low plasma Cav-1 level (P = 0.011 and P= 0.003, respectively). Of the 41 patients with MPC, 23 completed at least three cycles of chemotherapy. The median Cav-1 level was 13 ng/mL for post-treatment MPC (r2: 0.917; P= 0.001). High basal plasma caveolin-1 level have continued to remain at high levels even after chemotherapy, showing a trend toward worse response rates (P = 0.086).
High basal plasma Cav-1 levels seem to be associated with poor survival and tend to yield worse therapeutic outcomes in patients with MPC. This study is the first to evaluate the prognostic significance of plasma Cav-1 levels as a prognostic factor in patients with MPC. However, larger prospective clinical trials are warranted.
背景/目的：评估血浆小窝蛋白（CAV）-1在转移性胰腺癌（MPC）中的预后意义及其与生存率和治疗反应率的关系。
前瞻性收集41例新诊断MPC患者的血浆样本。此外，收集48例慢性胰腺炎患者和41例健康个体（对照组）的血浆样本以评估Cav-1水平。在MPC患者基线时及化疗三个周期后评估血浆Cav-1水平。
MPC患者的Cav-1水平中位数为13.8 ng/mL，健康个体为12.2 ng/mL（P = 0.009）。通过受试者工作特征曲线计算出Cav-1的截断水平为11.6 ng/mL。基础血浆Cav-1水平高的参与者的中位总生存期和无进展生存期分别为5个月和2.4个月；血浆Cav-1水平低的参与者相应值分别为10.5个月和9.4个月（分别为P = 0.011和P = 0.003）。41例MPC患者中，23例完成了至少三个周期的化疗。治疗后MPC患者的Cav-1水平中位数为13 ng/mL（r2：0.917；P = 0.001）。基础血浆小窝蛋白-1水平高的患者即使在化疗后仍持续保持高水平，显示出反应率较差的趋势（P = 0.086）。
基础血浆Cav-1水平高似乎与MPC患者的不良生存相关，并且往往产生较差的治疗结果。本研究首次评估了血浆Cav-1水平作为MPC患者预后因素的预后意义。然而，需要更大规模的前瞻性临床试验。
